

# PhytoHealth Corporation

Stock Code: 4108

## 2026 Investor Presentation

Presented by I-Ling Lee, President

Established: 1998

Listed on the Taiwan Stock Exchange: 2008

Paid-in Capital: NT\$1.986 billion

Chairperson: I-Li Lee

# Disclaimer

1. Except for historical information, statements in this presentation that express forward-looking views are subject to significant risks and uncertainties, which may cause actual results to differ from those expressed.
2. The outlook presented herein reflects the Company's current views of the future. The Company undertakes no obligation to update this information as a result of subsequent events or changes in circumstances.
3. Without the Company's permission, no part of this presentation may be reproduced, modified, recompiled, abridged, transmitted, or used for commercial purposes.
4. This presentation covers all entities included in the consolidated financial statements.

# Agenda

**01 Company Overview**

**02 Key Developments in 2025-2026**

**03 Financial Information**

# Company Overview

Caring for Health. With Exceptional Dedication.

## Science-based botanical drug development

PhytoHealth applies Western scientific validation to medicinal botanicals used in Chinese communities for thousands of years. We develop botanical drugs that meet conventional pharmaceutical standards to address unmet clinical needs.



# Milestones: A Clear Vision and Steady Progress

- 1998** Company established.
- 2002** Became the first new drug R&D company recommended by the Ministry of Economic Affairs for OTC listing as a technology stock.
- 2008** Became the first new drug R&D company to transfer from the OTC market to the TWSE under the Biotech and New Pharmaceutical Development Act.
- 2009-2012** PG2® Injection received the first prescription new drug approval issued after the TFDA was established.  
Completed the botanical drug purification plant and began commercial supply; the plant obtained MOHW PIC/S GMP certification.
- 2013-2020** Published Phase IV PG2® clinical trial results in an international journal.  
PG2® became a preferred drug in Taiwan's clinical guidelines for cancer-related fatigue.  
Oraphine® received TFDA new drug marketing approval.
- 2021-2026** PG2® included in Taiwan's National Health Insurance (NHI) reimbursement.  
Research presented at ASCO 2023 and ESMO 2024.  
Oraphine® expanded into international markets.

## R&D; Innovation

Two new drug approvals

## Clinical Engagement

Included in clinical guidelines

## International Expansion

Research presentations support market entry

**PhytoHealth Corporation**

# Achievements in New Drug Development

## Regulatory Recognition

- PG2® received the first new drug approval issued by Taiwan's TFDA (April 2010).
- PhytoHealth's plant became the first PIC/S GMP-certified botanical purification plant (September 2016).
- PhytoHealth holds 2 of the 10 TFDA-issued new drug approvals: PG2® for cancer-related fatigue and Oraphine® for moderate to severe pain (March 2020).

## Clinical Validation

- 30 PG2® research publications in top-quartile leading medical and oncology journals.
- Completed a Phase IV randomized, double-blind, multicenter PG2® trial (N=323).
- 20 clinical studies presented at ASCO, MASCC, WCP and TJCC.

## Market Acceptance

- PG2® was the first botanical new drug covered by NHI (March 2021).
- Adopted by 115 healthcare institutions, including 22 medical centers, 47 regional hospitals and 16 district hospitals.
- Continuing clinical experience in cancer-related fatigue: 800+ oncologists; 22,000+ patients; 14,000+ healthcare professionals receiving continuing education annually.

# A Proven Botanical Drug Commercialization Model



# Three Growth Engines for the Next Five Years



## **1** Core Growth

### **PG2®**

NHI reimbursement

Steady growth in self-pay sales

High market share

## **2** Global Expansion

### **Oraphine®**

The world's only oral formulation

Licensing in Europe and Southeast Asia

## **3** Long-term Diversification

### **Botanical Supplements**

Premium healthy-aging market

Ingredient partnerships with major international companies

# Key Developments in 2025–2026

Caring for Health. With Exceptional Dedication.

1

**PG2®: 15 Years Since Launch**


**From Cancer-related Fatigue Relief  
to Survival Outcomes**

**Establishing Standard-of-Care  
Combination Therapy in Oncology**

2

## **Advancing Oraphine® in Domestic and International Postoperative Pain Markets**

# Oraphine®: Redefining the Gold Standard in Acute Pain



# Oraphine®: An Oral Opioid for Multimodal Postoperative Analgesia



## Target self-pay postoperative pain market

Obstetrics and gynecology, orthopedics, neurosurgery and general surgery.

## Expand hospital adoption in Taiwan

Adopted by nearly 40 hospitals, including Hualien Tzu Chi Hospital, Tri-Service General Hospital, Kaohsiung Veterans General Hospital, Cheng Hsin General Hospital, the Mackay hospital system and Shin Kong Hospital.

## Build postmarketing real-world evidence

Multimodal analgesia after orthopedic surgery, abdominal surgery and plastic surgery.

# Initiating Product Registration in Germany

## Aristo Pharma

|                               |        |
|-------------------------------|--------|
| Manufacturing sites           | 5+     |
| Annual revenue (US\$ million) | 500+   |
| Employees                     | 1,780+ |
| Countries served              | 38+    |

## Progress with Aristo Pharma

Q1 2025: Signed a letter of intent for sales cooperation.

Q4 2025: Initiated regulatory consultation for German registration.

Q1 2026: Received feedback and began preparing submission documents.



Germany's analgesics market was US\$186 million in 2023 and is projected to reach US\$305 million by 2033, representing a CAGR of 5.07%.

# 3

## **Bringing Our Drug R&D Expertise to Health Supplements**

# Applying Patented Botanical Extraction to Functional Foods

3.0

## **Astragalus Polysaccharides**

### **rAPP® Astragalus Polysaccharides**

Enhanced performance

High-efficacy variety / Drug-development technology applied to food

2.0

## **Astragalus Extract**

Unknown variety / Cell walls disrupted; unpurified

1.0

## **Astragalus Slices**

Varieties without demonstrated efficacy / Incomplete cell-wall disruption by cooking or infusion

# Expanding Advanced Ingredients and Commercial Partnerships



## Proprietary Functional Ingredients

Focus on advanced R&D supported by clinical evidence.

## Domestic & Global Partnerships

Actively discussing functional ingredient partnerships with domestic and international health supplement companies.

## Consumer Health Applications

Capture global demand for healthy aging and wellness, establishing a foundation for steady long-term growth.

# Financial Information

Caring for Health. With Exceptional Dedication.

# Condensed Balance Sheet

Sound financial position: ample cash and low leverage

Unit: NT\$ thousands

| Item                                        | Jun 30, 2026     | %          | Dec 31, 2025     | %          |
|---------------------------------------------|------------------|------------|------------------|------------|
| Current assets                              | 1,179,387        | 48         | 1,263,922        | 53         |
| Non-current assets                          | 1,232,191        | 52         | 1,089,155        | 47         |
| <b>Total assets</b>                         | <b>2,411,578</b> | <b>100</b> | <b>2,353,077</b> | <b>100</b> |
| Current liabilities                         | 40,436           | 2          | 46,119           | 1          |
| Non-current liabilities                     | 17,784           | 1          | 13,305           | 1          |
| <b>Total liabilities</b>                    | <b>58,220</b>    | <b>3</b>   | <b>59,424</b>    | <b>2</b>   |
| Share capital                               | 1,986,189        | 82         | 1,986,189        | 85         |
| Capital surplus / accumulated losses, etc.  | (43,065)         | (3)        | (113,404)        | (5)        |
| Equity attributable to owners of the parent | 1,943,124        | 79         | 1,872,785        | 80         |
| Non-controlling interests                   | 410,234          | 19         | 420,868          | 18         |
| <b>Total equity</b>                         | <b>2,353,358</b> | <b>98</b>  | <b>2,293,653</b> | <b>98</b>  |
| <b>Total liabilities and equity</b>         | <b>2,411,578</b> | <b>100</b> | <b>2,353,077</b> | <b>100</b> |

# Condensed Statement of Comprehensive Income

Revenue up 14% YoY; loss down 41%.

Working toward profitability over the next two years.

Unit: NT\$ thousands, except EPS

| Item                                                 | Jan-Jun 2026<br>(A) | %            | Jan-Jun 2025<br>(B) | %            | Change<br>(%)<br>(A-B)/B |
|------------------------------------------------------|---------------------|--------------|---------------------|--------------|--------------------------|
| <b>Net revenue</b>                                   | <b>70,428</b>       | <b>100</b>   | <b>61,570</b>       | <b>100</b>   | <b>14</b>                |
| Gross profit                                         | 25,745              | 37           | 19,563              | 32           | 32                       |
| Operating expenses                                   | (97,850)            | (139)        | (101,828)           | (165)        | (4)                      |
| <b>Operating loss</b>                                | <b>(72,105)</b>     | <b>(102)</b> | <b>(82,265)</b>     | <b>(133)</b> | <b>(12)</b>              |
| Net non-operating income and expenses                | 24,990              | 36           | 17,444              | 28           | 43                       |
| Loss before tax                                      | (47,127)            | (66)         | (64,806)            | (105)        | (27)                     |
| Net loss - consolidated                              | (47,127)            | (66)         | (64,806)            | (105)        | (27)                     |
| <b>Net loss attributable to owners of the parent</b> | <b>(21,613)</b>     | <b>(31)</b>  | <b>(36,443)</b>     | <b>(59)</b>  | <b>(41)</b>              |
| <b>Earnings per share (NT\$)</b>                     | <b>(0.11)</b>       |              | <b>(0.18)</b>       |              |                          |



**Thank You!**

